Oncogenic micro-RNAs and renal cell carcinoma

Frontiers in Oncology

Volumn 4 MAR, Issue , 2014, Pages

  Grange, Cristina ^a   Collino, Federica ^b   Tapparo, Marta ^a   Camussi, Giovanni ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Cancer stem cells; Circulating miRNAs; EMT transition; Kidney; RCC biomarkers; Tumor plasticity

Indexed keywords

ANGIOPOIETIN 1; BETA ACTIN; CD133 ANTIGEN; CD24 ANTIGEN; CD9 ANTIGEN; CYCLIN DEPENDENT KINASE 6; ENDOGLIN; EPHRIN A3; EXPORTIN 1; FIBRONECTIN; GELATINASE A; GELATINASE B; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; RNA 5S; TRANSCRIPTION FACTOR SIX1; TRANSCRIPTION FACTOR SOX2; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN; VASCULOTROPIN; VIMENTIN;

CANCER RECURRENCE; CANCER STEM CELL; CELL MIGRATION; EPIGENETIC REPRESSION; EPITHELIAL MESENCHYMAL TRANSITION; GENETIC TRANSCRIPTION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; KIDNEY CARCINOMA; METASTASIS; MOLECULAR BEACON; MRNA EXPRESSION ASSAY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN METHYLATION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TUMOR VOLUME;

EID: 84901012046     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00049     Document Type: Review

References (106)

1. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature (2003) 425(6956):415-9. doi: 10.1038/nature01957.
2. Han J, Lee Y, Yeom KH, Kim YK, Jin H, Kim VN. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev (2004) 18(24):3016-27. doi:10.1101/gad.1262504.
3. Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA (2004) 10(2):185-91. doi:10.1261/rna.5167604.
4. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell (2009) 136(2):215-33. doi:10.1016/j.cell.2009.01.002.
5. Baer C, Claus R, Plass C. Genome-wide epigenetic regulation of miRNAs in cancer. Cancer Res (2013) 73(2):473-7. doi:10.1158/0008-5472.CAN-12-3731.
6. Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, La Noce M, et al. Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB J (2013) 27(1):13-24. doi:10.1096/fj.12-218222.
7. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med (1997) 3(7):730-7. doi:10.1038/nm0797-730.
8. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 100(7):3983-8. doi:10.1073/pnas.0530291100.
9. Grosse-Gehling P, Fargeas CA, Dittfeld C, Garbe Y, Alison MR, Corbeil D, et al. CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges. J Pathol (2013) 229(3):355-78. doi:10.1002/path.4086.
10. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature (2001) 414(6859):105-11. doi:10.1038/35102167.
11. Nimmo RA, Slack FJ. An elegant mirror: microRNAs in stem cells, developmental timing and cancer. Chromosoma (2009) 118(4):405-18. doi:10.1007/s00412-009-0210-z.
12. Wang ZM, Du WJ, Piazza GA, Xi Y. MicroRNAs are involved in the self-renewal and differentiation of cancer stem cells. Acta Pharmacol Sin (2013) 34(11):1374-84. doi:10.1038/aps.2013.134.
13. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, et al. Let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell (2007) 131(6):1109-23. doi:10.1016/j.cell.2007.10.054.
14. Peter ME. Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle (2009) 8(6):843-52. doi:10.4161/cc.8.6.7907.
15. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature (2000) 403(6772):901-6. doi:10.1038/35002607.
16. Golestaneh AF, Atashi A, Langroudi L, Shafiee A, Ghaemi N, Soleimani M. miRNAs expressed differently in cancer stem cells and cancer cells of human gastric cancer cell line MKN-45. Cell Biochem Funct (2012) 30(5):411-8. doi:10.1002/cbf.2815.
17. Bao B, Li Y, Ahmad A, Azmi AS, Bao G, Ali S, et al. Targeting CSC-related miRNAs for cancer therapy by natural agents. Curr Drug Targets (2012) 13(14):1858-68. doi:10.2174/138945012804545515.
18. Krichevsky AM, Gabriely G. miR-21: a small multi-faceted RNA. J Cell Mol Med (2009) 13(1):39-53. doi:10.1111/j.1582-4934.2008.00556.x.
19. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, et al. Down-regulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell (2009) 138(3):592-603. doi:10.1016/j.cell.2009.07.011.
20. Ji J, Yamashita T, Budhu A, Forgues M, Jia HL, Li C, et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology (2009) 50(2):472-80. doi:10.1002/hep.22989.
21. Liu B, Sun L, Song E. Non-coding RNAs regulate tumor cell plasticity. Sci China Life Sci (2013) 56(10):886-90. doi:10.1007/s11427-013-4554-5.
22. Smith AL, Iwanaga R, Drasin DJ, Micalizzi DS, Vartuli RL, Tan AC, et al. The miR-106b-25 cluster targets Smad7, activates TGF-β signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer. Oncogene (2012) 31(50):5162-71. doi:10.1038/onc.2012.11.
23. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 133(4):704-15. doi:10.1016/j.cell.2008.03.027.
24. Pencheva N, Tavazoie SF. Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol (2013) 15(6):546-54. doi:10.1038/ncb2769.
25. Li T, Li D, Sha J, Sun P, Huang Y. MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun (2009) 383(3):280-5. doi:10.1016/j.bbrc.2009.03.077.
26. Reis PP, Tomenson M, Cervigne NK, Machado J, Jurisica I, Pintilie M, et al. Programmed cell death 4 loss increases tumor cell invasion and is regulated by miR-21 in oral squamous cell carcinoma. Mol Cancer (2010) 9:238-51. doi:10.1186/1476-4598-9-238.
27. Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS, et al. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol (2008) 28:5369-80. doi:10.1128/MCB.00479-08.
28. Ma L. Role of miR-10b in breast cancer metastasis. Breast Cancer Res (2010) 12(5):210. doi:10.1186/bcr2720.
29. Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol (2008) 10(2):202-10. doi:10.1038/ncb1681.
30. Segura MF, Hanniford D, Menendez S, Reavie L, Zou X, Alvarez-Diaz S, et al. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci U S A (2009) 106(6):1814-9. doi:10.1073/pnas.0808263106.
31. Gaziel-Sovran A, Segura MF, Di Micco R, Collins MK, Hanniford D, Vega-Saenz de Miera E, et al. miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell (2011) 20(1):104-18. doi:10.1016/j.ccr.2011.05.027.
32. Crawford M, Brawner E, Batte K, Yu L, Hunter MG, Otterson GA, et al. MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun (2008) 373(4):607-12. doi:10.1016/j.bbrc.2008.06.090.
33. Wang G, Mao W, Zheng S. MicroRNA-183 regulates Ezrin expression in lung cancer cells. FEBS Lett (2008) 582(25-26):3663-8. doi:10.1016/j.febslet.2008.09.051.
34. Tavazoie SF, Alarcón C, Oskarsson T, Padua D, Wang Q, Bos PD, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature (2008) 451(7175):147-52. doi:10.1038/nature06487.
35. Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF, Morris PG, et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med (2011) 17(7):867-74. doi:10.1038/nm.2379.
36. Zhang J, Liang Q, Lei Y, Yao M, Li L, Gao X, et al. SOX4 induces epithelial-mesenchymal transition and contributes to breast cancer progression. Cancer Res (2012) 72(17):4597-608. doi:10.1158/0008-5472.CAN-12-1045.
37. Hamada S, Satoh K, Fujibuchi W, Hirota M, Kanno A, Unno J, et al. MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9. Mol Cancer Res (2012) 10(1):3-10. doi:10.1158/1541-7786.MCR-11-0272.
38. Feng R, Chen X, Yu Y, Su L, Yu B, Li J, et al. miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Lett (2010) 298(1):50-63. doi:10.1016/j.canlet.2010.06.004.
39. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szász AM, Wang ZC, et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell (2009) 137(6):1032-46. doi:10.1016/j.cell.2009.03.047.
40. Valastyan S, Chang A, Benaich N, Reinhardt F, Weinberg RA. Concurrent suppression of integrin alpha 5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis. Cancer Res (2010) 70(12):5147-54. doi:10.1158/0008-5472.CAN-10-0410.
41. Xia H, Qi Y, Ng SS, Chen X, Li D, Chen S, et al. microRNA-146b inhibits glioma cell migration and invasion by targeting MMPs. Brain Res (2009) 1269:158-65. doi:10.1016/j.brainres.2009.02.037.
42. Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M, et al. miR-205 exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase C epsilon. Cancer Res (2009) 69(6):2287-95. doi:10.1158/0008-5472.CAN-08-2894.
43. Kamm RC, Smith AG. Nucleic acid concentrations in normal human plasma. Clin Chem (1972) 18(6):519-22.
44. Camussi G, Deregibus MC, Bruno S, Grange C, Fonsato V, Tetta C. Exosome/microvesicle-mediated epigenetic reprogramming of cells. Am J Cancer Res (2011) 1(1):98-110.
45. Tetta C, Ghigo E, Silengo L, Deregibus MC, Camussi G. Extracellular vesicles as an emerging mechanism of cell-to-cell communication. Endocrine (2013) 44(1):11-9. doi:10.1007/s12020-012-9839-0.
46. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol (2007) 9(6):654-9. doi:10.1038/ncb1596.
47. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 105(30):10513-8. doi:10.1073/pnas.0804549105.
48. Lässer C, Alikhani VS, Ekström K, Eldh M, Paredes PT, Bossios A, et al. Human saliva, plasma and breast milk exosomes contain RNA: uptake by macrophages. J Transl Med (2011) 9:9. doi:10.1186/1479-5876-9-9.
49. Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res (2011) 39(16):7223-33. doi:10.1093/nar/gkr254.
50. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, et al. Argonaute 2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A (2011) 108(12):5003-8. doi:10.1073/pnas.1019055108.
51. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol (2011) 13(4):423-33. doi:10.1038/ncb2210.
52. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol (2008) 141(5):672-5. doi:10.1111/j.1365-2141.2008.07077.x.
53. Redova M, Sana J, Slaby O. Circulating miRNAs as new blood-based biomarkers for solid cancers. Future Oncol (2013) 9(3):387-402. doi:10.2217/fon.12.192.
54. Sheinerman KS, Umansky SR. Circulating cell-free microRNA as biomarkers for screening, diagnosis and monitoring of neurodegenerative diseases and other neurologic pathologies. Front Cell Neurosci (2013) 7:150. doi:10.3389/fncel.2013.00150.
55. Wang H, Peng W, Ouyang X, Li W, Dai Y. Circulating microRNAs as candidate biomarkers in patients with systemic lupus erythematosus. Transl Res (2012) 160(3):198-206. doi:10.1016/j.trsl.2012.04.002.
56. Mar-Aguilar F, Mendoza-Ramírez JA, Malagón-Santiago I, Espino-Silva PK, Santuario-Facio SK, Ruiz-Flores P, et al. Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis Markers (2013) 34(3):163-9. doi:10.3233/DMA-120957.
57. Madhavan D, Zucknick M, Wallwiener M, Cuk K, Modugno C, Scharpff M, et al. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin Cancer Res (2012) 18(21):5972-82. doi:10.1158/1078-0432.CCR-12-1407.
58. Silva J, García V, Zaballos á, Provencio M, Lombardía L, Almonacid L, et al. Vesicle-related microRNAs in plasma of non small cell lung cancer patients and correlation with survival. Eur Respir J (2011) 37(3):617-23. doi:10.1183/09031936.00029610.
59. Roth C, Rack B, Müller V, Janni W, Pantel K, Schwarzenbach H. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res (2010) 12(6):R90. doi:10.1186/bcr2766.
60. Brase JC, Johannes M, Schlomm T, Fälth M, Haese A, Steuber T, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer (2011) 128(3):608-16. doi:10.1002/ijc.25376.
61. Rathmell WK, Godley PA. Recent updates in renal cell carcinoma. Curr Opin Oncol (2010) 22(3):250-6. doi:10.1097/CCO.0b013e328337a5d2.
62. Lopez-Beltran A, Carrasco JC, Cheng L, Scarpelli M, Kirkali Z, Montironi R. Update on the classification of renal epithelial tumors in adults. Int J Urol (2009) 16(5):432-43. doi:10.1111/j.1442-2042.2009.02302.x.
63. Bausch B, Jilg C, Gläsker S, Vortmeyer A, Lützen N, Anton A, et al. Renal cancer in von Hippel-Lindau disease and related syndromes. Nat Rev Nephrol (2013) 9(9):529-38. doi:10.1038/nrneph.2013.
64. Fridman E, Dotan Z, Barshack I, David MB, Dov A, Tabak S. Accurate molecular classification of renal tumors using microRNA expression. J Mol Diagn (2010) 12(5):687-96. doi:10.2353/jmoldx.2010.090187.
65. Slaby O, Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, et al. Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes Chromosomes Cancer (2012) 51(7):707-16. doi:10.1002/gcc.21957.
66. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature (2005) 435(7043):834-8. doi:10.1038/nature03702.
67. Youssef YM, White NM, Grigull J, Krizova A, Samy C, Mejia-Guerrero S, et al. Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur Urol (2011) 59(5):721-30. doi:10.1016/j.eururo.2011.01.004.
68. Petillo D, Kort EJ, Anema J, Furge KA, Yang XJ, Teh BT. MicroRNA profiling of human kidney cancer subtypes. Int J Oncol (2009) 35(1):109-14. doi:10.3892/ijo_00000318.
69. Liu H, Brannon AR, Reddy AR, Alexe G, Seiler MW, Arreola A, et al. Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell renal cell carcinoma. BMC Syst Biol (2010) 4:51. doi:10.1186/1752-0509-4-51.
70. McCormick RI, Blick C, Ragoussis J, Schoedel J, Mole DR, Young AC, et al. miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. Br J Cancer (2013) 108(5):1133-42. doi:10.1038/bjc.2013.56.
71. Neves R, Scheel C, Weinhold S, Honisch E, Iwaniuk KM, Trompeter HI, et al. Role of DNA methylation in miR-200c/141 cluster silencing in invasive breast cancer cells. BMC Res Notes (2010) 3:219. doi:10.1186/1756-0500-3-219.
72. Hidaka H, Seki N, Yoshino H, Yamasaki T, Yamada Y, Nohata N, et al. Tumor suppressive microRNA-1285 regulates novel molecular targets: aberrant expression and functional significance in renal cell carcinoma. Oncotarget (2012) 3(1):44-57.
73. Chow TF, Mankaruos M, Scorilas A, Youssef Y, Girgis A, Mossad S, et al. The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma. J Urol (2010) 183(2):743-51. doi:10.1016/j.juro.2009.09.086.
74. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature (2013) 499(7456):43-9. doi:10.1038/nature12222.
75. Zaman MS, Thamminana S, Shahryari V, Chiyomaru T, Deng G, Saini S, et al. Inhibition of PTEN gene expression by oncogenic miR-23b-3p in renal cancer. PLoS One (2012) 7(11):e50203. doi:10.1371/journal.pone.0050203.
76. Wang G, Chen L, Meng J, Chen M, Zhuang L, Zhang L. Overexpression of microRNA-100 predicts an unfavorable prognosis in renal cell carcinoma. Int Urol Nephrol (2013) 45(2):373-9. doi:10.1007/s11255-012-0374-y.
77. Majid S, Saini S, Dar AA, Hirata H, Shahryari V, Tanaka Y, et al. MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer. Cancer Res (2011) 71(7):2611-21. doi:10.1158/0008-5472.
78. Yamasaki T, Seki N, Yamada Y, Yoshino H, Hidaka H, Chiyomaru T, et al. Tumor suppressive microRNA-138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma. Int J Oncol (2012) 41(3):805-17. doi:10.3892/ijo.2012.1543.
79. Williams AA, Higgins JP, Zhao H, Ljunberg B, Brooks JD. CD9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma. BMC Clin Pathol (2009) 9:9. doi:10.1186/1472-6890-9-9.
80. Girgis AH, Iakovlev VV, Beheshti B, Bayani J, Squire JA, Bui A, et al. Multilevel whole-genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma. Cancer Res (2012) 72(20):5273-84. doi:10.1158/0008-5472.CAN-12-0656.
81. Yoshino H, Enokida H, Itesako T, Kojima S, Kinoshita T, Tatarano S, et al. The tumor-suppressive microRNA-143/145 cluster targets hexokinase-2 in renal cell carcinoma. Cancer Sci (2013) 104(12):1567-74. doi:10.1111/cas.12280.
82. Cui L, Zhou H, Zhao H, Zhou Y, Xu R, Xu X, et al. MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma. BMC Cancer (2012) 12:546. doi:10.1186/1471-2407-12-546.
83. Khella HW, Bakhet M, Allo G, Jewett MA, Girgis AH, Latif A, et al. miR-192, miR-194 and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma. Carcinogenesis (2013) 34(10):2231-9. doi:10.1093/carcin/bgt184.
84. Wang X, Chen X, Wang R, Xiao P, Xu Z, Chen L, et al. microRNA-200c modulates the epithelial-to-mesenchymal transition in human renal cell carcinoma metastasis. Oncol Rep (2013) 30(2):643-50. doi:10.3892/or.2013.2530.
85. Wotschofsky Z, Liep J, Meyer HA, Jung M, Wagner I, Disch AC, et al. Identification of metastamirs as metastasis-associated microRNAs in clear cell renal cell carcinomas. Int J Biol Sci (2012) 8(10):1363-74. doi:10.7150/ijbs.5106.
86. Wu X, Weng L, Li X, Guo C, Pal SK, Jin JM, et al. Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One (2012) 7:e35661. doi:10.1371/journal.pone.0035661.
87. Wulfken LM, Moritz R, Ohlmann C, Holdenrieder S, Jung V, Becker F, et al. MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One (2011) 6(9):e25787. doi:10.1371/journal.pone.0025787.
88. Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R, et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med (2012) 10:55. doi:10.1186/1479-5876-10-55.
89. Hauser S, Wulfken LM, Holdenrieder S, Moritz R, Ohlmann CH, Jung V, et al. Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma. Cancer Epidemiol (2012) 36(4):391-4. doi:10.1016/j.canep.2012.04.001.
90. Zhao A, Li G, Péoc'h M, Genin C, Gigante M. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol (2013) 94(1):115-20. doi:10.1016/j.yexmp.2012.10.005.
91. Teixeira AL, Ferreira M, Silva J, Gomes M, Dias F, Santos JI, et al. Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients. Tumour Biol (2013). doi:10.1007/s13277-013-1531-3.
92. Mlcochova H, Hezova R, Stanik M, Slaby O. Urine microRNAs as potential noninvasive biomarkers in urologic cancers. Urol Oncol (2014) 32:.e1-9. doi:10.1016/j.urolonc.2013.04.011.
93. Von Brandenstein M, Pandarakalam JJ, Kroon L, Loeser H, Herden J, Braun G, et al. MicroRNA 15a, inversely correlated to PKCa, is a potential marker to differentiate between benign and malignant renal tumors in biopsy and urine samples. Am J Pathol (2012) 180(5):1787-97. doi:10.1016/j.ajpath.2012.01.014.
94. Bussolati B, Bruno S, Grange C, Ferrando U, Camussi G. Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB J (2008) 22(10):3696-705. doi:10.1096/fj.08-102590.
95. Grange C, Tapparo M, Collino F, Vitillo L, Damasco C, Deregibus MC, et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res (2011) 71(15):5346-56. doi:10.1158/0008-5472.CAN-11-0241.
96. Luedde T. MicroRNA-151 and its hosting gene FAK (focal adhesion kinase) regulate tumor cell migration and spreading of hepatocellular carcinoma. Hepatology (2010) 52(3):1164-6. doi:10.1002/hep.23854.
97. Zhang X, Zhu W, Zhang J, Huo S, Zhou L, Gu Z, et al. MicroRNA-650 targets ING4 to promote gastric cancer tumorigenicity. Biochem Biophys Res Commun (2010) 395(2):275-80. doi:10.1016/j.bbrc.2010.04.005.
98. Gebeshuber CA, Zatloukal K, Martinez J. miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep (2009) 10(4):400-5. doi:10.1038/embor.2009.9.
99. Chow TF, Youssef YM, Lianidou E, Romaschin AD, Honey RJ, Stewart R, et al. Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin Biochem (2010) 43(1-2):150-8. doi:10.1016/j.clinbiochem.2009.07.020.
100. Hauptman N, Glavac D. MicroRNAs and long non-coding RNAs: prospects in diagnostics and therapy of cancer. Radiol Oncol (2013) 47(4):311-8. doi:10.2478/raon-2013-0062.
101. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene (2007) 26(19):2799-803. doi:10.1038/sj.onc.1210083.
102. Kim JK, Choi KJ, Lee M, Jo MH, Kim S. Molecular imaging of a cancer-targeting theranostics probe using a nucleolin aptamer- and microRNA-221 molecular beacon-conjugated nanoparticle. Biomaterials (2012) 33(1):207-17. doi:10.1016/j.biomaterials.2011.09.023.
103. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol (2010) 12(3):247-52. doi:10.1038/ncb2024.
104. Kelnar K, Peltier HJ, Leatherbury N, Stoudemire J, Bader AG. Quantification of therapeutic miRNA mimics in whole blood from nonhuman primates. Anal Chem (2014) 86(3):1534-42. doi:10.1021/ac403044t.
105. Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S, et al. MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther (2009) 16(3):206-16. doi:10.1038/cgt.2008.77.
106. Faragalla H, Youssef YM, Scorilas A, Khalil B, White NM, Mejia-Guerrero S, et al. The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma. J Mol Diagn (2012) 14(4):385-92. doi:10.1016/j.jmoldx.2012.02.003.